Knowledge of BRCA1 and BRCA2 status in NSCLC could play a role in medical management based on the clinical rationale that BRCA-altered tumors are more sensitive to platinum salts [45]. This evidence concerns the gene BRCA2 and non-small cell lung carcinoma.